L. Mellars

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

Harold Bays, Paul B. Moore, Margaret Drehobl et al. · Clinical Therapeutics · 2001 · 312 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer

Alan Keller, Robert Mennel, Vassilis A. Georgoulias et al. · Journal of Clinical Oncology · 2004 · 212 citations · Full text

Medicine, Oncology, Pharmacology +16

Real-world burden of comorbidities in US patients with psoriasis

K. Shah, L. Mellars, Arun Changolkar et al. · Journal of the American Academy of Dermatology · 2017 · 89 citations · Full text

Medicine, Dermatology, Clinical Epidemiology +13

Real-world burden of comorbidities in US patients with psoriatic arthritis

K. Shah, Maria Paris, L. Mellars et al. · RMD Open · 2017 · 81 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +13